A Phase 3 interventional study of Psilocybin and Psilocybin in Major Depression, sponsored by VA Office of Research and Development. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by VA Office of Research and Development · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing psilocybin in Depressive Disorder, Major — 11 open to participants now, 16 under way, 4 of them phase 3. Psilocybin · Depressive Disorder, Major.
Among the 31 studies testing psilocybin in Depressive Disorder, Major, this one is the 2nd largest by planned enrollment, is one of 5 that started in 2026, is one of 4 in phase 3, reaches primary completion later than 14 of the 15 other live ones, and was the 25th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →11 of the 31 studies testing psilocybin in Depressive Disorder, Major are open now, in 7 countries. Recruiting first, the newest first:
Khyber Medical University Peshawar · Sites in Pakistan
Ages 18–60
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
University Medical Center Groningen · Sites in Czechia, Denmark, Netherlands and 1 more country
Ages 18+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–64
University of Texas at Austin · Sites in United States
Ages 22–65
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 240 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 35 across the 31 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 31 have an industry lead sponsor. The 10 most frequent:
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
25 studies in Depressive Disorder, Major by VA Office of Research and Development: 7 open now, 7 under way, 1 of them phase 3. Of 16 finished, 14 (88%) have results posted.
Among the 25 studies in Depressive Disorder, Major by VA Office of Research and Development, this one is the 7th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 3, and was the 24th registered.
VA Office of Research and Development’s Depressive Disorder, Major studies by the year they started, since 2010.
4 of the studies testing psilocybin in Depressive Disorder, Major that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07703722Phase 3Khyber Medical University PeshawarEffect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder | 2027-10-22 |
| NCT06782724University Medical Center GroningenPsilocybin Therapy for Psychological Distress in Palliative Patients | 2027-01-01 |
| NCT05947383Sunstone MedicalTwo Doses of Psilocybin for the Treatment of MDD in Adults With Cancer | 2027-04-30 |
| NCT07479550Stanford UniversityStudy of Psilocybin Under Anesthesia Controlled by EEG | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies testing psilocybin in Depressive Disorder, Major, from their registry updates:
Among VA Office of Research and Development’s 25 in Depressive Disorder, Major:
This tab as a report to print or save as PDF → With an account.
The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.
Treatment-resistant depression (TRD) is a serious mental health problem in Veterans, frequently comorbid with post-traumatic stress disorder (PTSD), and in need of novel and effective treatments. Clinical studies have revealed antidepressant effects of psilocybin for depression in civilians, but less is known about its efficacy and safety in Veterans. Very limited data is available on the effects of psilocybin in the treatment of PTSD. Thus, it is important to evaluate the safety and efficacy of psilocybin in the treatment of TRD with and without PTSD among Veterans.
The purpose of this multi-site, double-blind, randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of TRD in U.S. military Veterans with and without (±) concurrent PTSD. Eligible and consenting Veterans will two psilocybin dosing sessions along with preparation, administration, and integration psychological support provided by a facilitator. For the 1st psilocybin administration, participants will be randomized to one of two doses under blinded conditions. One month later, all participants will receive the same dose at their 2nd psilocybin visit. Outcomes will be measured by an independent evaluator masked from all treatments at 2 and 4 weeks after each dosing session. Longer-term follow-up will be conducted over 6 months. Both expected and unanticipated adverse events will be collected by type, severity and relatedness to the study drug.
The criteria were revised on the registry on Oct 23, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Psilocybin comparator dose
Drug: Psilocybin
Psilocybin intervention dose
Drug: Psilocybin
Psilocybin comparator dose
Also known as: COMP360
Psilocybin Intervention Dose
Also known as: COMP360
Montgomery-Asberg Rating Scale (MADRS)
10-item clinician-administered rating scale for depression. Scored 0 to 60; higher score indicates more severe symptomatology.
Time frame: 2 weeks
Swiss Psychedelic Side Effects Inventory Overall Score
A clinician guided self-report form that has a list of effects pertaining to psychedelics; has the option to add other side effects (or expected effects) as desired and includes an open text field to provide additional details that are not captured in the inventory list. In addition to rating severity of the side effects, the SPSI captures impact, causality, timing and duration, and has a global rating on tolerability. Scoring: Calculate total scores for the number of side effects, severity, and impact by adding the relevant columns. Calculate total scores for the number of side effects, severity, and impact by adding the relevant columns. The overall score is calculated by subtracting total severity from total impact. The overall score represents the burden of side effects for that person within the specified timeframe.
Time frame: one day
Clinician-Administered PTSD Scale for DSM-5 - Revised
A 30-item interview used to rate the past-month PTSD severity in those participants diagnosed with PTSD by CAPS-5-R at baseline. Higher score (0 to 200) indicates higher PTSD severity.
Time frame: one month
Hamilton Depression Rating Scale
A validated rater-administered measure of depression severity. The 17-item version yields a score of 0 to 50; higher score indicates more severe depression.
Time frame: two weeks
Patient Health Questionnaire 9
A 9-item self-report measure designed to characterize severity of depression; has excellent psychometrics, total score range 0 to 27, higher = more severe.
Time frame: two weeks
PTSD Checklist for DSM-5
A 20-item self-report of PTSD symptoms; score 0-80; higher=more severe. Only collected in those with PTSD diagnosis at baseline.
Time frame: one month
Plan to share: Yes — De-identified data and a data dictionary will be shared pending required IRB approval, and if needed, a Data Use Agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: At the conclusion of the study after a data repository has been made operational.
Access criteria: De-identified data of those participants who signed informed consent, to include baseline demographics and clinical characteristics, primary outcome measure over time, treatment assignment, secondary safety outcomes, and exploratory outcomes. Data will be available for 6 years after the closure of the main study.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Dec 2030, 51 months after the start.
Of 123 phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 36. This study's planned 51 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
VA Office of Research and Development →